Starting with a severely affected family, a research research team led by Jeanette Erdmann, Christian Hengstenberg and Heribert Schunkert (Institut für Integrative und Experimentelle Genomik, University of Lübeck and Deutsches Herzzentrum München) identified a novel mechanism leading to myocardial infarction. Specifically, the scientists detected two mutations that jointly blocked nitric oxide signalling in platelets leading to accelerated thrombus formation.
Another variant of the same enzyme, affecting a large proportion of the population, was also found to affect coronary risk, albeit to a much lesser extend. The project was funded by the DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e. V.). The work was published on November 10th in the prestigious journal Nature.
Coronary artery disease and its sequelae myocardial infarction are among the leading causes of death worldwide. In addition to an unhealthy lifestyle, it is known for a long time that familial or inherited factors contribute to the development of these diseases. Now, an international team of 42 researchers from 36 institutions and 7 countries unravelled a novel cause of myocardial infarction in an extraordinary large German family comprising more than 23 affected family members.
Next-generation sequencing made it feasible to pinpoint disease-causing mutations.
“In our case the surprising finding was that two mutations affecting the same enzyme came together in a family with an extraordinary high myocardial infarction risk“ adds Heribert Schunkert from the Deutsches Herzzentrum Munich. Jeanette Erdmann specifies: „We identified two private mutations in the functionally related genes, GUCY1A3 and CCT7. Extensive follow-up studies revealed that these genes encode proteins that work together to mediate effects following nitric oxide stimulation which, among other actions, inhibit platelet activation“.
“Overall, these data suggest a link between impaired nitric oxide signalling and myocardial infarction risk“ summarizes Christian Hengstenberg from the Deutsches Herzzentrum München. Jeanette Erdmann adds, “Furthermore, we show that it is important not only to search for one disease-causing mutation in families, but to look for two, or even three potentially interacting mutations to explain clustering of a disease in families”.Background
Here, the researchers sequenced, in cooperation with colleagues at the Helmholtz-Zentrum Munich (Tim Strom and Thomas Meitinger), the complete coding regions of the genome (the so-called “exome“) of three affected cousins and looked for mutations shared by these family members and absent in healthy controls. Starting with more than 30.000 of such genetic variants the researches were left in the end with two mutations in GUCY1A3 and CCT7 encoding for proteins that actually interact functionally in an enzyme called soluble guanylyl cyclase (sGC). In fact, if both mutations were found in a family member the effect was a dysfunctional enzyme incapable of responding to nitric oxide stimulation. The effect was by far less if only one of the the mutations were found in a family member.
A subunit of the enzyme soluble guanylyl cyclase (sGC) that is well known to be activated by nitric oxide is encoded by GUCY1A. The second mutation was found in the gene CCT7 which encodes a chaperone protein required for proper folding of newly synthetized cellular proteins. In a cell-based approach, the researchers demonstrated in cooperation with cellular biologists (Frank Kaiser from the Institute of Human Genetics of the University of Lübeck and Doris Koesling from the Institute of Pharmacology and Toxicology of the University of Bochum) that lack of this chaperone protein reduces the cellular amount of sGC resulting in loss of sGC function. Thus, both proteins are required for intact nitric oxide signalling. An important target of nitric oxide signalling are platelets in which aggregation is inhibited by this intercellular messenger. These cells can be easily isolated from the blood and, indeed, were found to be non-responsive to nitric oxide stimulation due to a substantial reduction of sGC protein levels in family members caarying both mutations. Likewise, all family members carrying both mutations developed coronary disease. Reversing this defect may provide a new therapeutic target for reducing the risk of myocardial infarction.
The importance of the nitric oxide signalling pathway on the functional level was verified by a cooperation with Cor de Wit, a physiologist from the Institute of Physiology of the University of Lübeck, who demonstrated accelerated platelet aggregation in mice deficient for this critical subunit of the sGC. The finding in the mice which mimicks the situation in double mutation carriers may provide the mechanistic link between dysfunctional nitric oxide signalling and myocardial infarction since platelet aggregation and thrombus formation may be unopposed in affected individuals rendering them prone for this fatal disease.
Interestingly, genetic data of more than 30.000 MI patients and 80.000 controls pulled together from the international consortium CARDIoGRAM provide evidence that not only very rare mutations in GUCY1A3 lead to MI but also common variants in this gene increases MI risk substantially.Title of publication:
For further information, please contact:Prof. Dr. rer. nat. Jeanette Erdmann
Christine Vollgraf | idw
Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg
The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Physics and Astronomy
08.12.2016 | Health and Medicine
08.12.2016 | Life Sciences